Long-Term Benefits of Composite Treatment Targe...

By HEOR Staff Writer

January 21, 2026

Sustained Composite Treatment Targets Enhance Clinical and Economic Outcomes in Type 2 Diabetes A recent modeling study examines the lon...
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases
Novartis Drug Pricing Agreement
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...